The creation of these implants is a direct answer to the demands of patients who need primary or revision reconstruction following a mastectomy.
Johnson&Johnson
In a Phase 3 trial, investigational icotrokinra led to 66% of scalp psoriasis patients and 77% of genital psoriasis patients achieving clear or almost clear skin specifically on those affected sites by Week 16.
Johnson & Johnson today announced significant long-term findings from the Phase 3 QUASAR study program, demonstrating that TREMFYA® (guselkumab) delivered sustained rates of clinical remission and endoscopic improvement in adult patients with moderately to severely active ulcerative colitis (UC) through two years of continuous treatment. These compelling results underscore the […]
IMAAVY demonstrated a swift and significant decrease in IgG levels, a primary driver of gMG, in key adult and pediatric trials.
The Phase 3 VENTURA research study, which was assessing aticaprant as an adjunctive treatment for major depressive disorder (aMDD), has been discontinued by Johnson & Johnson because of its lack of effectiveness in the target patient population. No new safety signals were found, and the results verified that aticaprant is […]
